Profile data is unavailable for this security.
About the company
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
- Revenue in USD (TTM)0.00
- Net income in USD-44.81m
- Incorporated2001
- Employees14.00
- LocationGalectin Therapeutics IncSUITE 2404960 PEACHTREE INDUSTRIAL BOULEVARDNORCROSS 30071United StatesUSA
- Phone+1 (678) 620-3186
- Fax+1 (770) 864-1327
- Websitehttps://galectintherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prelude Therapeutics Inc | 0.00 | -121.83m | 204.85m | 128.00 | -- | 0.8639 | -- | -- | -2.05 | -2.05 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -48.91 | -47.21 | -53.60 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 208.20m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Renovaro Inc | 0.00 | -41.23m | 211.19m | 12.00 | -- | 2.29 | -- | -- | -0.685 | -0.685 | 0.00 | 0.6431 | 0.00 | -- | -- | 0.00 | -59.63 | -27.81 | -72.82 | -28.44 | -- | -- | -- | -- | -- | -22.12 | 0.1299 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
Eliem Therapeutics Inc | 0.00 | -35.12m | 212.29m | 9.00 | -- | 1.95 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Lineage Cell Therapeutics Inc | 8.95m | -21.49m | 213.04m | 75.00 | -- | 3.12 | -- | 23.82 | -0.1243 | -0.1243 | 0.0518 | 0.3624 | 0.0796 | -- | 17.17 | 119,266.70 | -19.12 | -19.53 | -22.55 | -22.59 | 92.50 | 89.13 | -240.12 | -370.88 | -- | -- | 0.0023 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
G1 Therapeutics Inc | 82.51m | -47.97m | 215.58m | 100.00 | -- | 6.06 | -- | 2.61 | -0.953 | -0.953 | 1.53 | 0.6815 | 0.5332 | 0.5028 | 6.94 | 825,110.00 | -31.00 | -47.06 | -39.28 | -52.64 | 91.28 | -- | -58.13 | -268.59 | 3.45 | -5.22 | 0.593 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
Compass Therapeutics Inc. | 0.00 | -42.49m | 216.02m | 32.00 | -- | 1.35 | -- | -- | -0.3343 | -0.3343 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -23.84 | -41.75 | -25.56 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
Galectin Therapeutics Inc | 0.00 | -44.81m | 216.66m | 14.00 | -- | -- | -- | -- | -0.7456 | -0.7456 | 0.00 | -0.9739 | 0.00 | -- | -- | 0.00 | -165.97 | -92.08 | -394.92 | -121.97 | -- | -- | -- | -- | -- | -12.72 | 6.24 | -- | -- | -- | -15.26 | -- | -- | -- |
Ovid Therapeutics Inc | 391.69k | -52.34m | 216.68m | 40.00 | -- | 2.46 | -- | 553.19 | -0.7415 | -0.7415 | 0.0056 | 1.24 | 0.0026 | -- | -- | 9,792.25 | -34.98 | -20.78 | -37.27 | -23.27 | -- | -- | -13,362.34 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 217.69m | -- | -- | 11.47 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
Veru Inc | 15.93m | -64.59m | 218.11m | 189.00 | -- | 4.23 | -- | 13.69 | -0.758 | -0.758 | 0.177 | 0.3525 | 0.1728 | 1.01 | 5.10 | 84,285.19 | -70.07 | -42.91 | -101.20 | -54.41 | 50.31 | 72.41 | -405.44 | -104.96 | 2.79 | -- | 0.1584 | -- | -58.59 | 0.5394 | -10.84 | -- | 67.39 | -- |
Elevation Oncology Inc | 0.00 | -45.70m | 218.55m | 29.00 | -- | 3.10 | -- | -- | -1.53 | -1.53 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -49.88 | -- | -55.94 | -- | -- | -- | -- | -- | -- | -12.22 | 0.3548 | -- | -- | -- | 51.93 | -- | -- | -- |
Codexis Inc | 70.14m | -76.24m | 219.43m | 174.00 | -- | 2.51 | -- | 3.13 | -1.12 | -1.12 | 1.03 | 1.24 | 0.3625 | 5.43 | 2.31 | 403,120.70 | -39.41 | -17.13 | -50.48 | -20.23 | 81.74 | 77.29 | -108.69 | -37.04 | 2.53 | -- | 0.00 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
Boundless Bio Inc | 0.00 | -49.43m | 222.39m | 72.00 | -- | -- | -- | -- | -2.22 | -2.22 | 0.00 | 5.42 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
AVITA Medical Inc | 50.14m | -35.38m | 223.17m | 207.00 | -- | 4.53 | -- | 4.45 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.40 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Dec 2023 | 1.92m | 3.11% |
Osaic Wealth, Inc. (Investment Management)as of 31 Dec 2023 | 1.25m | 2.02% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 711.27k | 1.15% |
Geode Capital Management LLCas of 31 Dec 2023 | 514.42k | 0.83% |
Geneos Wealth Management, Inc.as of 31 Dec 2023 | 412.65k | 0.67% |
Western International Securities, Inc.as of 31 Dec 2023 | 249.80k | 0.40% |
Wealthspire Advisors LLCas of 31 Dec 2023 | 183.86k | 0.30% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 178.74k | 0.29% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 161.44k | 0.26% |
Cambridge Investment Research Advisors, Inc.as of 31 Mar 2024 | 121.14k | 0.20% |